在阿尔茨海默病连续体中神经心理症状的神经表现,使用基于病理的功能连接分析
Taein Lee1, Yong Jeong1,
1Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.
Brain and behavior
|September 2, 2025
概括
阿尔茨海默病的神经心理症状与特定脑部区域的粉样β和陶积累有关. 这项研究确定了与情感和冷漠症状相关的关键领域和功能联系.
科学领域:
- 神经科学
- 阿尔茨海默病的研究
- 神经成像
背景情况:
- 神经精神症状 (NPS) 对阿尔茨海默病患者和护理人员产生重大影响.
- 了解NPS的神经机制对于改善患者护理至关重要.
- 之前的神经成像研究还没有充分探讨与NPS相关的功能网络的粉样β和tau病理的区域相互作用.
研究的目的:
- 通过整合分子 (粉样β,tau) 和功能 (功能连接性) 数据来识别NPS的神经相关物.
- 调查粉样β和tau病理的区域共存及其与特定NPS因子的关联.
主要方法:
- 使用了来自阿尔茨海默病神经成像计划 (ADNI) 数据库的数据,包括PET,fMRI和NPS得分.
- 根据NPS因子 (情感,冷漠,过度活跃,精神病) 使用神经精神科目录 (NPI) 分类参与者.
- 通过种子分析对受影响地区的区域性粉样β和tau积累进行比较,并分析功能连接差异.
主要成果:
- 在NPS组之间发现了粉样β,tau积累和功能连接的显著差异.
- 右中旋 (rMTG) 与情感因素有关,而右侧海马和状旋则与冷漠有关.
- 一个通用线性模型成功地根据rMTG和左上边缘/角旋转之间的功能连接性预测了情感因子的严重性.
结论:
- 确定了与情感和冷漠因素相关的关键大脑区域.
- 这些区域显示出粉样β和蛋白病理的共存以及功能连接的改变.
- 这些发现为阿尔茨海默病中特定的NPS的神经基础提供了洞察力.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Neural Regulation
39.9K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.9K
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260


